Prognosis after splenectomy plus pericardial devascularization vs transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding

doi:10.4240/wjgs.v15.i8.1641

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3080)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1421

Figures (1-2)

242

Tables (1-5)

244

Sum=2019

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

208

Download

735

Sum=943

Aug 27, 2023 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Aug 27, 2023; 15(8): 1641-1651
Published online Aug 27, 2023. doi: 10.4240/wjgs.v15.i8.1641

Table 1 Baseline features of the study population

Characteristic	Before PSM			After PSM
Characteristic	SPD group	TIPS group	P value	SPD group	TIPS group	P value
Age, yr	44.14 ± 10.64	49.57 ± 11.24	< 0.001	46.41 ± 10.81	47.16 ± 10.95	0.65
Male, n (%)	121 (74.7)	105 (67.3)	0.15	64 (71.1)	60 (66.7)	0.520
Bleeding history, mo	12.70 ± 24.19	12.83 ± 21.95	0.961	13.64 ± 26.76	13.6 ± 22.62	0.99
Spleen length, cm	20.121 ± 4.49	19.27 ± 4.05	0.08	19.86 ± 4.47	18.85 ± 3.57	0.10
Spleen thickness, cm	6.47 ± 1.43	6.20 ± 1.42	0.09	6.31 ± 1.29	6.05 ± 1.07	0.14
TB, μmol/L	22.81 ± 9.93	22.18 ± 10.22	0.58	23.68 ± 10.60	21.99 ± 9.65	0.26
ALT, IU/L	34.561 ± 27.68	32.08 ± 35.49	0.49	29.81 ± 19.33	29.34 ± 15.25	0.86
AST, IU/L	40.651 ± 29.05	41.218 ± 35.80	0.88	36.37 ± 22.78	37.32 ± 18.09	0.76
ALB, g/L	37.71 ± 5.28	33.13 ± 6.19	< 0.001	36.35 ± 4.58	35.46 ± 5.15	0.22
A/G	1.311 ± 0.29	1.52 ± 3.40	0.45	1.31 ± 0.27	1.28 ± 0.29	0.58
ALP, IU/L	87.10 ± 39.98	85.08 ± 52.93	0.70	86.42 ± 37.50	86.93 ± 57.34	0.94
GGT, IU/L	50.13 ± 59.94	49.26 ± 61.59	0.90	53.35 ± 71.03	49.14 ± 63.91	0.68
BUN, mmol/L	6.038 ± 7.87	5.89 ± 2.76	0.82	6.48 ± 10.44	5.56 ± 2.00	0.42
CREA, μmol/L	72.92 ± 17.01	73.02 ± 18.40	0.96	73.20 ± 18.54	69.36 ± 14.59	0.13
HGB, g/L	99.74 ± 27.85	84.38 ± 23.18	< 0.001	94.42 ± 30.02	91.07 ± 23.76	0.41
RBC, × 10¹²/L	3.71 ± 0.82	3.06 ± 0.79	< 0.001	3.46 ± 0.81	3.39 ± 0.79	0.54
PLT, × 10⁹/L	51.85 ± 43.11	55.13 ± 37.11	0.47	50.76 ± 45.62	52.86 ± 24.49	0.70
WBC, × 10⁹/L	3.68 ± 3.85	3.59 ± 3.93	0.83	3.10 ± 2.56	3.38 ± 2.26	0.43
PT, s	14.67 ± 3.79	14.76 ± 2.08	0.79	14.38 ± 1.95	14.21 ± 1.75	0.54
INR	1.27 ± 0.17	1.32 ± 0.19	0.02	1.28 ± 0.17	1.27 ± 0.15	0.46
HBV-DNA Positive	80 (49.4)	81 (51.9)	0.65	47 (52.2)	48 (53.3)	0.88
Child-Pugh classification, n (%)			0.17			1.00
A	89 (54.9)	75 (48.1)		49 (54.4)	49 (54.4)
B	73 (45.1)	81 (51.9)		41 (45.6)	41 (45.6)
Severe EGV, n (%)	131 (80.9)	124 (79.5)	0.78	73 (81.1)	74 (82.2)	1.00

SPD: Splenectomy plus pericardial devascularization; TIPS: Transjugular intrahepatic portosystemic shunt; TB: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; A/G: Albumin/globulin; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; HGB: Hemoglobin; RBC: Red blood cell count; WBC: White blood cell count; PLT: Platelets; PT: Prothrombin time; INR: International normalized ratio; HBV: Hepatitis B virus; EGV: Esophagogastric varices; PSM: Propensity score-matched analysis.

Table 2 Univariate and multivariate Cox regression analyses of factors associated with death

Variable	Univariable analysis		Multivariable analysis
	HR (95%CI)	P value¹	HR (95%CI)	P value
Treatment strategy (SPD vs TIPS)	0.43 (0.24-0.78)	0.005	0.47 (0.25-0.90)	0.02
Age, per 1-year increase	1.04 (1.02-1.07)	0.001	1.03 (1.01-1.06)	0.02
TB, per 1 μmol/L increase	1.03 (1.01-1.06)	0.01
ALB, per 1 g/L increase	0.94 (0.91-0.98)	0.004
A/G, per 1 increase	0.06 (0.02-0.18)	< 0.001	0.11 (0.03-0.48)	0.003
ALP, per 1 IU/L increase	1.01 (1.00-1.01)	< 0.001
GGT, per 1 IU/L increase	1.003 (1.00-1.01)	0.03
PT, per 1 s increase	1.07 (1.02-1.12)	0.004	1.09 (1.02-1.16)	0.01
INR, per 1 increase	6.38 (1.68-24.24)	0.006
HBV-DNA (Positive vs negative)	1.78 (1.00-3.15)	0.05
Child-Pugh classification (B vs A)	1.83 (1.07-3.15)	0.03

¹Variables that were found significant at P < 0.1 in the univariable analyses were entered into the multivariable analyses. SPD: Splenectomy plus pericardial devascularization; TIPS: Transjugular intrahepatic portosystemic shunt; TB: Total bilirubin; ALB: Albumin; A/G: Albumin/globulin; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; PT: Prothrombin time; INR: International normalized ratio; HBV: Hepatitis B virus.

Table 3 Proportions of 1-, 3-, and 5-year cumulative variceal rebleeding, abnormal liver function, and hepatocellular carcinoma in the two groups before and after propensity score matching, %

Outcome/Time	Before PSM			After PSM
Outcome/Time	SPD group	TIPS group	P value¹	SPD group	TIPS group	P value¹
Variceal rebleeding
1-yr	8.60	20.50	0.001	7.80	11.10	0.09
3-yr	19.10	34.60		15.65	27.80
5-yr	24.10	37.80		23.30	31.10
Abnormal liver function
1-yr	13.60	48.70	< 0.001	13.30	46.70	< 0.001
3-yr	19.80	57.70		18.90	53.30
5-yr	22.80	60.30		20.00	56.70
Hepatocellular carcinoma
1-yr	2.50	3.80	0.03	2.20	4.40	0.02
3-yr	3.70	9.00		2.20	10.00
5-yr	4.90	11.50		2.20	12.20

¹Log-rank test was used to compare the differences between the two groups for each outcome event. SPD: Splenectomy plus pericardial devascularization; TIPS: Transjugular intrahepatic portosystemic shunt; PSM: Propensity score-matched analysis.

Table 4 Multivariate Cox regression analysis of factors associated with variceal rebleeding, abnormal liver function, and hepatocellular carcinoma

Outcome/Variable	HR (95%CI)	P value
Variceal rebleeding
Treatment strategy (SPD vs TIPS)	0.58 (0.37-0.89)	0.01
GGT, per 1 IU/L increase	1.005 (1.001-1.008)	0.01
HGB, per 1 g/L increase	0.99 (0.98-1.00)	0.01
Abnormal liver function
Treatment Strategy (SPD vs TIPS)	0.26 (0.17-0.39)	< 0.001
TB, per 1 μmol/L increase	1.03 (1.02-1.05)	< 0.001
ALP, per 1 IU/L increase	1.004 (1.000-1.007)	0.03
PT, per 1 s increase	1.06 (1.00-1.13)	0.045
Hepatocellular carcinoma
Treatment Strategy (SPD vs TIPS)	0.43 (0.20-0.93)	0.03
TB, per 1 μmol/L increase	1.03 (1.00-1.07)	0.045
ALP, per 1 IU/L increase	1.006 (1.000-1.012)	0.043

SPD: Splenectomy plus pericardial devascularization; TIPS: Transjugular intrahepatic portosystemic shunt; TB: Total bilirubin; ALB: albumin; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; PT: Prothrombin time; HGB: Hemoglobin.

Table 5 Comparison of postoperative hospital days and number of reoperations and adverse events between the two groups

Variable	SPD group	TIPS group	P value
Postoperative hospital stay, days	9.5 ± 3.4	6.6 ± 3.9	< 0.001
Reoperation, times	5	92	< 0.001
In-hospital mortality	1	1	0.98
The 90-d mortality	1	4	0.21
The 30-d readmission	1	22	< 0.001
Occurrence of hepatic encephalopathy	1	25	< 0.001

SPD: Splenectomy plus pericardial devascularization; TIPS: Transjugular intrahepatic portosystemic shunt.

Citation: Qi WL, Wen J, Wen TF, Peng W, Zhang XY, Shen JY, Li X, Li C. Prognosis after splenectomy plus pericardial devascularization vs transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding. World J Gastrointest Surg 2023; 15(8): 1641-1651
URL: https://www.wjgnet.com/1948-9366/full/v15/i8/1641.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i8.1641